DXL

DXL is a biotechnology company focused on developing next-generation precision medicines for the treatment of cancer. The company leverages its proprietary DXL platform to design and optimize small molecule inhibitors and antibody-drug conjugates (ADCs) that target key DNA damage response (DDR) pathways. DXL's lead programs are currently in the pre-clinical stage, with a focus on addressing unmet needs in solid tumors, including breast, ovarian, and prostate cancers. By integrating advanced computational modeling with deep biological insights, DXL aims to deliver highly selective and potent therapies that overcome resistance to current standards of care.